Business Wire

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

Share

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005517/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alistair Johnson is Chief Professional Services Officer at Congenica (Photo: Business Wire)

Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a fully automated data analysis application, aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice.

To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.

GenomOncology’s Precision Oncology Platform is designed to harmonize the latest precision oncology information, which includes an extensive set of annotations and ontologies, as well as curated public, licensed, and proprietary content and data sets. By incorporating this comprehensive knowledgebase, Congenica will have improved access to curated, precision oncology information from the United States, United Kingdom, European Union, and others, to yield data-driven insights and recommendations within their CDS.

Alistair Johnson, Chief Professional Services Officer at Congenica, said: “This collaboration signifies the expansion of Congenica’s Clinical Decision Support (CDS) Platform into oncology. Our novel product offers a fully automated future-proof end-to-end solution that unlocks the full potential of Next Generation Sequencing (NGS) in the clinical oncology space. GenomOncology brings extensive experience in precision oncology care, and its platform has been developed specifically to deliver clinical informatics solutions for cancer. We look forward to working with GenomOncology to further drive precision medicine, delivering high quality patient care and shaping the future of human health.”

“Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level. The extensive information available within the GenomOncology Precision Oncology Platform, combined with the capabilities of the Congenica Clinical Decision Support Platform, will give clinicians and researchers the knowledge needed to provide their patients with the most appropriate care opportunities,” said Brad Wertz, Chief Executive Officer at GenomOncology.

About Congenica
Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers and clinicians to provide life-changing answers that improve wellbeing and disease management. Congenica’s world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

A recognised leader in the genomic analysis of rare diseases and inherited cancer, Congenica is expanding its platform into new indications such as somatic cancer, next generation non- invasive pre-natal diagnosis and wellness, helping to deliver a future where clinical genomics is fully integrated into healthcare.

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

www.congenica.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Becky Lamont, Marketing Communications Manager
00 44 (0)7468 698315
becky.lamont@congenica.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ikotek Expands Executive Management Team to Continue Rapid Growth of Its ODM Services Across North America and EMEA Regions29.9.2022 15:00:00 CEST | Press release

Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/ Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire) Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception. Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy acr

Norway comes top in Arthur D. Little’s Global Electric Mobility Readiness Index29.9.2022 14:52:00 CEST | Press release

Arthur D. Little (ADL) has published the latest edition of its Global Electric Mobility Readiness Index – GEMRIX 2022 – which details how favourable different markets are around the world to electric vehicle (EV) adoption. One of its key findings is that the country most ready for widespread EV uptake is Norway. GEMRIX 2022 has been produced to assist EV decision makers and track global EV uptake. Based on a detailed analysis of key market drivers and using standardized evaluation metrics, GEMRIX 2022 details the readiness of 15 countries for electric mobility. A GEMRIX score of 100 and higher means that it’s equally beneficial to buy and operate an EV as an internal combustion engine (ICE)-based vehicle – with a score of 115, Norway is the only country where this is currently the case. The rest of the benchmarked countries can be broadly categorised into three clusters according to their level of readiness for EV adoption: China, Germany, UK and Singapore are Ambitious Followers, with

Winning Again! FEELM Max Awarded the Golden Leaf Award for "Most Promising Innovation"29.9.2022 14:45:00 CEST | Press release

FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won the Golden Leaf Award for "Most Promising Innovation" at the 2022 Global Tobacco and Nicotine Forum (GTNF) in Washington, DC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005491/en/ GTNF event site (Photo: Business Wire) “Using FEELM’s updated ceramic coil technology, the FEELM Max offers improved flavor consistency, more puffs and reduced harshness through smaller aerosol particles. Most importantly, the FEELM Max offers greater potential for harm reduction,” the organizer of GTNF announced at the award ceremony. Four years ago, FEELM tech won the Golden Leaf Award. And four years later, FEELM Max won the Golden Leaf Award again, it is also FEELM Max's second global award this year after winning the Red Dot Award. The Golden Leaf Award is one of the most prestigious awards in the sector and is des

S64 Bolsters Pioneering Team With Strategic Hires Amid Surging Demand for Private Markets Products29.9.2022 14:05:00 CEST | Press release

S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020. S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs. Strategic hires following rapid growth Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deu

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies29.9.2022 14:00:00 CEST | Press release

As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s expertise in training and education toward the development of innovative solutions to global challenges and Takeda’s deep knowledge of rare disease and the plasma ecosystem. Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally. This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom